Multiple Myeloma (MM) is a malignancy characterized by clonal expansion of plasma cells. In 50% of the cases, the neoplastic transformation begins with a chromosomal translocation that juxtaposes the IGH gene locus to an oncogene. After defining the IGH-translocations present in a panel of MM cell lines, we conducted expression-profiling analysis. Supervised analysis identified 166 genes significantly differentially expressed among the cell lines harboring MMSET/FGFR3 (4p16), MAF (16q) and CCND1 (11q13) rearrangements. Besides translocations, gene copy number changes are also frequent in MM but far less characterized than in other neoplasias. We conducted array Comparative Genomic Hybridization (arrayCGH) with the same cDNA platform that was used for the expression analysis with the double purpose of characterizing the amplified genome regions and identifying the amplified and overexpressed (A/O) genes within these regions. We focused in five chromosomes recurrently affected by gains/amplifications in primary samples and cell lines where we found 60 A/O genes. Among them, twenty-five (42%) were only overexpressed when amplified, and six, CHI3L1, ELMO1, BNIP3L, PLAG1, LOC157567, and VPS28, showed a significant association between overexpression and gain/amplification.

In a second step, we are conducting a high resolution analysis of copy number changes in flow sorted CD138 myeloma cells from patients with normal karyotype, as stated by conventional cytogenetics. We are using the Human Genome CGH Microarray 44A platform from Agilent Technologies (Palo Alto, CA), which contains 44.000 60-mer oligonucleotides covering the human genome with an average resolution of 40 Kb. As expected, this genomic approach, performed on selected cells, allowed the identification of a high number of deletions and gains. We have found small regions (below 500 Kb of size) that were rearranged as follows:

Copy number changes on selected CD138+ MM cells

Chromosome RearrangementSome genes of biological interest loss
1p12-p21.3 STXBP3, SORT1, HRMT1L6, PSMAS 
loss 6q24.1–q24.2 STXBP5, IL20RA, MYB 
loss 11q14.1–q22.3 MMP1, 3, 7, 8, 10, 12, 13, 20, BIRC2 & 3 
loss 14q12–q21.3 FOXA, FBXO33, SNX6 
loss 16p12.1 TP53TG3, ZNF267, CREBPB 
gain 1q21 CKS1B, AIM2, SELL, CHI3L1 
gain 8q24.12–q24.23 C-MYC, PTK2 
Chromosome RearrangementSome genes of biological interest loss
1p12-p21.3 STXBP3, SORT1, HRMT1L6, PSMAS 
loss 6q24.1–q24.2 STXBP5, IL20RA, MYB 
loss 11q14.1–q22.3 MMP1, 3, 7, 8, 10, 12, 13, 20, BIRC2 & 3 
loss 14q12–q21.3 FOXA, FBXO33, SNX6 
loss 16p12.1 TP53TG3, ZNF267, CREBPB 
gain 1q21 CKS1B, AIM2, SELL, CHI3L1 
gain 8q24.12–q24.23 C-MYC, PTK2 

Work funded by Red Tematica FIS G03/136: Mieloma multiple y otras ganmapatias: de la genesis a la terapeutica. Spanish Ministry of Health

Author notes

Corresponding author

Sign in via your Institution